Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants

• Príomhchruthaitheoirí: Xue‐Qing Li (Údar), Bo Lindmark (Údar), Carl Amilon (Údar), Kristin Samuelsson (Údar), Lars Weidolf (Údar), Karin Nelander (Údar), Jane Knöchel (Údar), Maria Heijer (Údar), Ryan A. Bragg (Údar), Malin Gränfors (Údar), Eva‐Lotte Lindstedt (Údar), Sharan Sidhu (Údar), Pavlo Garkaviy (Údar), Hans Ericsson (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Wiley, 2024-10-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [14C]atuliflapon suspension was administered to six healthy male subjects. Mass...